Product expansion The recent launches of Luna Ti, Ventana A ALIF, and the Ventana 3D-Printed Interbody Portfolio indicate an active product expansion strategy in spinal implants and instrumentation. This suggests opportunities to cross-sell perioperative systems, instrumentation, and biologics to surgeons adopting these new platforms.

FDA clearance FDA 510(k) clearance for Ventana A ALIF reinforces credibility and accelerates adoption potential in the anterior lumbar space. Target surgeons and hospital procurement teams focusing on compliant, approved technologies with shorter time-to-market.

Strategic partnerships Spinal Elements demonstrates ongoing collaboration through publications and conference presence, signaling openness to partnerships, training programs, and value-based demos with key spine centers to accelerate adoption of new systems.

Growth trajectory With revenue in the $25–50 million range and a growing product portfolio, there is momentum for scale. Opportunities exist in expanding with multi-year supply agreements, service contracts, and volume-based pricing for larger hospital networks.

Tech-enabled sales Adoption of ERP and analytics tools (SAP, NetSuite, Power BI, HubSpot) indicates data-driven sales and CRM capabilities. Leverage these systems to identify high-potential accounts, tailor value propositions, and accelerate cycle times for new platforms.